Selank: The Anxiolytic Peptide
Last updated: March 2026
Selank is a synthetic heptapeptide derived from the immunomodulatory peptide tuftsin, developed at Russia's Institute of Molecular Genetics. It modulates GABA receptor function with anxiolytic effects comparable to benzodiazepines — without the sedation, cognitive impairment, or dependence risk.
Heptapeptide
Target System
Russia
📋 On this page
What Is Selank?
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a modified tuftsin analog with a Pro-Gly-Pro tripeptide extension that stabilizes it against enzymatic degradation. It was developed for treating generalized anxiety disorder and neurasthenia.
Allosterically modulates GABAA receptors, altering the expression of genes involved in GABAergic neurotransmission — including GABRA2, GABRA6, and GABRB2 subunit genes.
Influences serotonin, dopamine, and norepinephrine metabolism. Stabilizes enkephalin degradation, extending the activity of endogenous opioid peptides.
Derived from tuftsin, retains immunomodulatory properties. Influences IL-6 and interferon expression, bridging the neuro-immune axis.
Increases brain-derived neurotrophic factor expression, providing potential neuroprotective effects alongside its anxiolytic action.
What the Research Shows
Context: Selank was approved in Russia in 2009 for anxiety and neurasthenia. Clinical data predominantly comes from Russian institutions. The anxiolytic effects are well-documented, but Western clinical data is limited.
Side Effects & Safety Profile
Study Citations
Self-Assessment
Who Researches Selank?
This Research Is Commonly Explored By People Who...
- Are interested in anxiolytic alternatives without benzodiazepine dependence risk
- Want to understand GABAergic modulation via peptide-based approaches
- Are exploring the intersection of immune modulation and anxiety
- Are interested in Russian-developed nootropic/anxiolytic peptides
This Research May Not Be Relevant If...
- You want FDA-approved anxiety treatments — Selank is not available in the US
- You prefer oral medications — Selank requires intranasal administration
- You want extensive Western clinical trial data — most data is from Russian institutions
Want the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
Get the Guide →
Key Takeaways
- Anxiolytic effects comparable to benzodiazepines
- No sedation, cognitive impairment, or dependence
- Modulates GABAA receptor gene expression
- Approved in Russia since 2009
- Also has immunomodulatory properties
- Not FDA approved — no Western clinical trials
- Limited long-term safety data
- Exact binding mechanism still under investigation
- Requires intranasal administration (no oral form)
🔬 Verified Research Source
Third-party tested compounds from Swiss Chems — one of the most trusted research suppliers.
Affiliate link — supports HighPeptides at no extra cost. All Swiss Chems products include third-party lab testing certificates.
Research Supplies
Tools and supplies relevant to this research area.
As an Amazon Associate, HighPeptides earns from qualifying purchases.
Selank is NOT FDA approved in the United States. It is approved in Russia for anxiety and neurasthenia. This page is for educational purposes only. Not medical advice. Approved Russia Not Available US